Grounded in the Patient Experience
Transforming Delivery and
Accessibility of Next-gen Therapies
Terrestrial is developing the Tacterra™ microarray patch (MAP) platform, capable of delivering a wide range of therapies.
Using the skin as a delivery pathway, the Tacterra™ MAP features dissolvable tips made from advanced biomaterials—enabling precise dose delivery and control without the pain and hassle of an injection.
Terrestrial is transforming the delivery of next-gen therapies, such as GLP-1.
Creating a Radically
More Comfortable,
More Convenient Path to Better Health
Terrestrial is mapping out a future where treatments are easier to use and available wherever patients are. At Terrestrial, we envision a future where receiving therapies is dramatically more convenient, comfortable and aligned with everyday life. By removing sharps and eliminating the need for refrigeration, the Tacterra™ platform enables therapeutics to be self-administered in the comfort of a patient’s own home, on the go or while traveling.
“Terrestrial’s focus on the patient experience, combined with innovative engineering and design, will offer patients the option to receive novel, effective therapies – which would otherwise require injection – in a radically more convenient, pain-free way. It is incredibly motivating and inspiring to work towards impacting health at a global scale.”
- Rachel Sha, Terrestrial CEO